After losing the bidding for Medtronic to Pfizer, the CEO of Novo and Novartis turned their sights to a new target.

According to informed sources, owners of Wegovy and Ozempic, Novo Nordisk, will continue to focus on opportunities in the field of obesity, diabetes, and related complications. The company has always viewed Metsera Inc. as a potential complementary transaction rather than a transformative acquisition. Novo Nordisk stated in a statement that the company will "evaluate business development and acquisition opportunities that meet its return and capital allocation criteria and can further achieve its strategic goals."